Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)

NCT03893487 is registered in ClinicalTrials.gov with Sabine Mueller, MD, PhD as lead sponsor.

NCT NCT03893487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03893487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)
Lead sponsor
Sabine Mueller, MD, PhD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 7, 2019
Completion date
August 31, 2027
Enrollment
30 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma, recurrent anaplastic astrocytoma, recurrent glioblastoma, recurrent malignant glioma, recurrent medulloblastoma